TransMedics Group, Inc. $TMDX Shares Purchased by Congress Asset Management Co.

Key Points

• Congress Asset Management increased its TransMedics position by 11% in the third quarter, adding 25,118 shares to own 252,952 shares valued at approximately $21.1 million. Institutional investors collectively hold 99.67% of the company.
• Director David Weill purchased 1,336 shares at an average price of $81.63, raising his stake by 8.87%; insiders own 6.90% of TransMedics stock.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above analyst estimates, but EPS of $0.44 missed consensus by $0.06. Analysts maintain a consensus “Hold” rating with an average price target of $121.10.

Congress Asset Management Co. grew its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 11.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 252,952 shares of the company's stock after purchasing an additional 25,118 shares during the period. Congress Asset Management Co. owned approximately 0.73% of TransMedics Group worth $21,109,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TMDX. Ascentis Independent Advisors bought a new position in TransMedics Group in the 1st quarter worth approximately $30,000. North Star Investment Management Corp. acquired a new position in shares of TransMedics Group during the first quarter valued at $30,000. Titan Wealth CI Ltd bought a new stake in shares of TransMedics Group during the fourth quarter valued at about $40,000. Silvant Capital Management LLC acquired a new stake in TransMedics Group in the second quarter worth about $26,000. Finally, Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 95.0% in the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 425 shares of the company's stock valued at $45,000 after buying an additional 207 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In other news, Director David Weill bought 1,336 shares of the company's stock in a transaction dated Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the transaction, the director directly owned 16,392 shares in the company, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 6.90% of the company's stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $80.28 on Wednesday. TransMedics Group, Inc. has a one year low of $60.10 and a one year high of $156.00. The stock has a fifty day moving average of $85.86 and a 200-day moving average of $84.45. The company has a market capitalization of $2.77 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 1.14 and a beta of 1.94. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The company had revenue of $189.95 million during the quarter, compared to analyst estimates of $184.00 million. During the same quarter in the previous year, the firm earned $0.92 earnings per share. The business's revenue was up 20.7% compared to the same quarter last year. As a group, equities analysts anticipate that TransMedics Group, Inc. will post 1.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on the stock. Weiss Ratings upgraded shares of TransMedics Group from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, August 31st. Canaccord Genuity Group reissued a "buy" rating and set a $124.00 target price on shares of TransMedics Group in a report on Tuesday, June 30th. Piper Sandler restated an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research report on Wednesday, August 5th. Stifel Nicolaus increased their price target on TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, June 18th. Finally, UBS Group lowered their price target on TransMedics Group from $80.00 to $77.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, TransMedics Group has an average rating of "Hold" and a consensus target price of $121.10.

About TransMedics Group

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.